Literature DB >> 2163238

Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected rhesus macaques: relationship to clinical and viral status.

M P Heyes1, I N Mefford, B J Quearry, M Dedhia, A Lackner.   

Abstract

Increased concentrations of excitotoxin quinolinic acid in cerebrospinal fluid (CSF) are associated with infection with the human immunodeficiency virus (HIV-1) and have been implicated in the pathogenesis of the acquired immune deficiency syndrome (AIDS) dementia complex. In the present study, inoculation of macaques with D/1/California, an immunosuppressive serotype 1 type D retrovirus, was associated with acute and chronic increases in CSF and serum quinolinic acid concentrations in macaques that had developed SAIDS, a simian disease analogous to AIDS in humans--particularly macaques with demonstrable opportunistic infections. Kynurenic acid, an antagonist of excitatory amino acid receptors as well as the excitotoxic effects of quinolinic acid, was also increased in the CSF of SAIDS macaques, but to a significantly lesser degree than was quinolinic acid (kynurenic acid, 1.8-fold; quinolinic acid, 15.6-fold). CSF quinolinic acid, but not kynurenic acid, was also increased in viremic macaques with SAIDS-related complex (2.4-fold) and asymptomatic virus positive carriers (3.4-fold). Macaques that had recovered from D/1/California infection and were antibody positive and virus negative had normal CSF quinolinic acid and kynurenic acid concentrations. Increased activity of indoleamine-2,3-dioxygenase, the first enzyme of the kynurenine pathway, was indicated in the macaques with SAIDS by reduced serum L-tryptophan and elevated serum L-kynurenine concentrations. Macaques infected with D/1/California may provide a primate model for investigation of the mechanisms involved in increases in CSF quinolinic acid in retrovirus and other infectious diseases, including HIV-1. It remains to be determined whether the increased CSF quinolinic acid concentrations and the increased ratio of quinolinic acid to kynurenic acid have neurological significance or are a useful "marker" of infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163238     DOI: 10.1002/ana.410270614

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  N-methyl-D-aspartate preconditioning prevents quinolinic acid-induced deregulation of glutamate and calcium homeostasis in mice hippocampus.

Authors:  S Vandresen-Filho; P C Severino; L C Constantino; W C Martins; S Molz; T Dal-Cim; D B Bertoldo; F R M B Silva; C I Tasca
Journal:  Neurotox Res       Date:  2014-11-04       Impact factor: 3.911

Review 2.  Animal models for depression associated with HIV-1 infection.

Authors:  Isabella Cristina Gomes Barreto; Patricia Viegas; Edward B Ziff; Elisabete Castelon Konkiewitz
Journal:  J Neuroimmune Pharmacol       Date:  2013-12-12       Impact factor: 4.147

3.  Changes in kynurenic, anthranilic, and quinolinic acid concentrations in rat brain tissue during development.

Authors:  G Cannazza; A Chiarugi; C Parenti; P Zanoli; M Baraldi
Journal:  Neurochem Res       Date:  2001-05       Impact factor: 3.996

Review 4.  Kynurenines in the mammalian brain: when physiology meets pathology.

Authors:  Robert Schwarcz; John P Bruno; Paul J Muchowski; Hui-Qiu Wu
Journal:  Nat Rev Neurosci       Date:  2012-07       Impact factor: 34.870

5.  Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid.

Authors:  M P Heyes; K Saito; S P Markey
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

6.  Induction of pterin synthesis is not required for cytokine-stimulated tryptophan metabolism.

Authors:  N Sakai; K Saito; S Kaufman; M P Heyes; S Milstien
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

7.  Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD).

Authors:  Jon Salemi; Demian F Obregon; Anthony Cobb; Spenser Reed; Edin Sadic; Jingji Jin; Francisco Fernandez; Jun Tan; Brian Giunta
Journal:  Mol Neurodegener       Date:  2011-01-11       Impact factor: 14.195

Review 8.  Kynurenines in CNS disease: regulation by inflammatory cytokines.

Authors:  Brian M Campbell; Erik Charych; Anna W Lee; Thomas Möller
Journal:  Front Neurosci       Date:  2014-02-06       Impact factor: 4.677

9.  N-Methyl D-Aspartate Receptor Antagonist Kynurenic Acid Affects Human Cortical Development.

Authors:  Inseyah Bagasrawala; Nada Zecevic; Nevena V Radonjić
Journal:  Front Neurosci       Date:  2016-09-30       Impact factor: 4.677

Review 10.  3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future.

Authors:  Isaac Túnez; Inmaculada Tasset; Verónica Pérez-De La Cruz; Abel Santamaría
Journal:  Molecules       Date:  2010-02-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.